Corporate
News release
TopTOKYO, JAPAN - August 29, 2019 - Terumo Corporation (TSE: 4543), a leading global medical device manufacturer, today announced that it will invest in two U.S.-based venture capital funds, Strategic Healthcare Investment Partners (S.H.I.P) with offices in Silicon Valley, California, and Dublin, Ireland, and Catalyst Health Ventures (CHV) with offices in Boston, Massachusetts. Terumo will invest USD 25 million in each fund, in total USD 50 million.
Venture investing in the medtech field can complement internal R&D with new technology, expanded strategy, and also further complement business development and acquisition. In that light, Terumo has utilized this strategy previously, as a Limited Partner of Emergent Medical Partners (EMP) since 2013, including having a Terumo liaison work with the fund. Terumo has reviewed more than 2,000 startups over the last 6 years based on its network built through this relationship. While investing in the fund, Terumo also directly invested in multiple startups. These activities contribute to Terumo's internal capabilities, giving access to new technology collaborations and acquisitions that fits its business strategy.
Now, Terumo will expand this activity with presence on the U.S. West Coast and East Coast, including having a liaison in both funds. This enables Terumo to be involved in more geographically and technically diversified deals. The Company's breadth of relationships will be enhanced from early to late stage technologies, aiming to deliver solutions for large unmet medical needs.
About Terumo
Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.